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Cholera, a prototypical secretory diarrheal disease, is an ancient scourge that has both wrought
great suffering and taught many valuable lessons, from basic sanitation to molecular signal trans-
duction. Victims experience the voluminous loss ofbicarbonate-rich isotonic saline at a rate that
may leadto hypovolemic shock, metabolic acidosis, anddeath withinafewhours. Intravenous solu-
tion therapy as we know it wasfirst developed in an attempt toprovide life-saving volume replace-
mentfor cholera patients. Breakthroughs in epithelial membrane transportphysiology, such as the
discovery ofsugar andsalt cotransport, havepaved the wayfor oral replacement therapy in areas
ofthe world where intravenous replacement is not readily available. In addition, the discovery of
the cholera toxin has yielded vital information about toxigenic infectious diseases, providing a
framework in which to studyfundamental elements ofintracellular signal transduction pathways,
such as G-proteins. Cholera may even shed light on the evolution and pathophysiology ofcystic
fibrosis, the most commonly inherited disease among Caucasians.
The goal ofthis paper is to review, using case studies, some ofthe lessons learnedfrom cholera
throughout the ages, acknowledging those pioneers whose seminal work led to our understanding
ofmany basic concepts in medical epidemiology, microbiology, physiology, and therapeuticsf
INTRODUCTION
Cholera is an infectious disease
whose course can vary from a mild diar-
rheal syndrome to a rapidly fatal malady
(cholera gravis) characterized by the sud-
den onset of profuse watery diarrhea with
volume depletion, metabolic acidosis, and
ultimately death from hypovolemic shock.
The disease is caused by Vibrio cholerae,
a short, curved, bacterium thatproduces an
enterotoxin (choleragen). Humans are the
only known host for cholera vibrios [1],
which can spread rapidly though a com-
munity primarily via fecal contamination
ofdrinking water.
Throughout its history, cholera caused
widespread panic because it can afflict an
otherwise healthy person without warning
and lead to death in as little as four to six
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hours. Many victims have awoken with
uncompromised health at the edge of the
day and died gruesomely in their own
dejecta before night's retum. More recent-
ly in several parts of the world, cholera
pandemics have claimed thousands of
lives in outbreaks in southern Africa and
Latin America.
We will present three case scenarios
based on actual patients illustrating many
of the clinical manifestations of cholera.
These will be used as a springboard to
review 1) the colorful history of cholera
including its impact on the origin ofintra-
venous solution therapy, 2) the fundamen-
tal physiological principles that underlie
the disease and its treatment, and 3) how
aspects of cholera have intertwined with
developments in modern science.
CHOLERA: SYMPTOMS, SIGNS,
ANDTHE ORIGIN OF INTRA-
VENOUSTHERAPY
Case Scenario 1:
Sunderland, Britain, 1831 [2]
A 25-year-old woman was found in
grave distress. The patient was too lethar-
gic to provide a history, but a friend states
that she was in her usual state of good
health until 24 hours previously when she
developed the acute onset of profuse
watery diarrhea, vomiting, and muscle
cramps. The villagers had collected all of
her diarrheal fluid in a canister kept near
the patient, since they believed that part of
the reason she was so ill was that herbody
had been depleted ofvital substances con-
tained in the excretions. No other history
was available except that several other vil-
lagers had already died from this type of
illness. The first death in Sunderland had
been on Oct. 26, 1831.
On physical examination, the patient
was extremely weak and lethargic. The
silver-bluish color of her skin was remi-
niscent of lead. She was cool to the touch
and had poor skin turgor. The wrinkled
skin on her hands appeared as if it had
been immersed in water for a prolonged
time ("washerwomen's hands"). Herfacial
features were flattened and her eyes were
sunk deep into their sockets. Aradial pulse
was not palpable, but a heart rate of 160
per minute was assessed by listening over
the chest. The patient's breathing was
labored, at a rate of 32 breaths per minute
(hyperventilation in response to metabolic
acidosis), but breath sounds over the lung
fields were clear. The abdomen was soft.
The extremities were cold and there was
no peripheral edema.
Inspection of the canister showed
approximately ten liters ofnearly odorless
watery fluid containing flecks of mucus
("rice-water" stools). Sensing the gravity
of the patient's condition, the apothecary
boiled eight gallons (30 liters) of water
and prepared two solutions:
Solution #1: 5 gallons (-19 liters) ofa
solution containing by weight 9 parts sodi-
umchloride to 1000 parts water (0.9% iso-
tonic NaCl).
Solution #2: 3 gallons (-11 liters) ofa
solution containing 12.6 parts soda of
bicarbonate to 1000 parts water (isotonic
bicarbonate solution).
As the patient was sinking towards
death, and as the bewildered townspeople
looked on, a hollow silver needle
(designed by John Read [3]) was placed in
the right femoral vein and attached to a
breast pump syringe by a flexible tube
fashioned from goose trachea. A quart of
the NaCl solution was injected overfifteen
minutes, followed by a pint of the
NaHCO3 solution over the next fifteen
minutes. Three parts potassium chloride
was also added to 1000 parts Solution #1
(KCI 40 meq/l) in a few quarts. After five
cycles of this treatment, to the astonish-
ment of all who had gathered, the patient
became alert and animated. Her radial
pulse returned at a rate of 112 per minute.
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alternating fashion, until the patient stated
that her bladder was full. By that time she
had received eight quarts ofthe NaCl solu-
tion (four containing KCI) and eight pints
of the NaHCO3 solution, a total of over
eleven liters.
The patient continued to pass "rice-
water" stools and required sixteen liters of
intravenous solution therapy the next day
(Figure 1). By the fifth day, the diarrhea
had significantly decreased, but the patient
had not passed any urine since day three.
Despite the valiant intravenous solution
replacement therapy, the patient died of
progressive renal failure on day twenty [4].
Nevertheless, this was the birth of intra-
venous solution therapy as we know it.
CHOLERA INTHE UNITED STATES:
EFFECTIVE THERAPY
Case Scenario 2:
Port Lavaca, Texas, 1973 [5]
A 51-year-old man presented to the
emergency department with a four-hour
history of profuse watery, non-bloody
diarrhea. The patient noted mild abdomi-
nal pain along with non-odorous diarrhea,
and experienced one episode of emesis.
The patient also complained of severe leg
cramps.
On initial physical examination, no
blood pressure could be obtained. The
pulse was auscultated at 150 beats per
minute, and Kussmaul-type respirations
were present at a rate of thirty breaths per
minute. The patient was afebrile, alert and
oriented. The abdominal findings were
minimal - soft, scaphoid abdomen, non-
tender to palpation, with active bowel
sounds. His extremities were noted to have
"splotchy" cyanosis, and no peripheral
pulses were palpable.
Initial laboratory values included a
white blood cell count of 13,400 per ml,
hemoglobin of 18.1 g/dl, [Na] 136 meq/l,
[K] 3.1 meq/l, [CO2] 18 meq/l and BUN
40 mg/dl. Two hours after admission, a
second total CO2 level was only 5 meq/l.
Central venous access was obtained and
intravenous lactated Ringer's solution
infused. Supplemental potassium and
bicarbonate was administered, along with
intravenous gentamicin. After six hours,
the patient's condition improved signifi-
cantly, with full return ofperipheral pulses
and intact mental status.
The attending physician reviewed the
literature and found his patient's symp-
toms were compatible with cholera,
althoiugh no cases of domestically
acquired cholera had been reported in the
United States since 1911 [6]. The physi-
cian switched the antibiotic regimen to
tetracycline and alerted the local health
authorities. The diagnosis of cholera was
confirmed by laboratory culture, which
identified Vibrio cholerae, El Tor biotype,
Inaba serotype. Further volume resuscita-
tion ensued, and the patient was dis-
charged home in good health one week
from initial presentation.




A 29-year-old man presented to the
clinic with a ten-hour history of diarrhea
and a seven-hour history of vomiting. The
patient could provide no further coherent
history. On examination, thepatient was in
mild distress, disoriented to place and time
but talkative. The patient was afebrile,
tachycardic, and had a blood pressure of
90/60. The patient had sunken eyes and
poor skin turgor, but otherwise had an
unremarkable exam.
Based on local disease patterns, the
patient was treated with the presumptive
diagnosis of cholera, which was subse-
quently confirmed with darkfield illumina-
tion ofthe stool. The patient was given six396 Kavic et al.: Cholera: medical history and science
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Figure 1. Chart of the total input, total output, and stool output for the patient
described in case scenario one. Note that stool accounts for nearly all the output
throughout the hospital course, and that initial stool output approached ten liters per day.
The patient died of oliguric renal failure on hospital day 20.
hours of intravenous therapy with Dhaka
solution [6]: [Na] 133 mmol/l, [K] 13
mmol/l, [Cl] 98 mmol/l, and [acetate] 48
mmol/1), for a total volume of six liters.
This solution provides the volume, potas-
sium, and bicarbonate (as acetate is con-
verted to bicarbonate in the liver) required
to offset the massive losses of these elec-
trolytes in the diarrhea of cholera. Ery-
thromycin therapy was also instituted, 500
mg every six hours for three days.
At the completion of the initial resus-
citation, the patient was coherent and
showed no signs of systemic infection.
The intravenous fluids were discontinued.
The patient was given World Health Orga-
nization Oral Rehydration Solution
(WHO-OHS), containing [Na] 90 mmol/l,
[K] 20 mmol/l, [Cl] 80 mmol/l, [citrate] 10
mmol/l (which is metabolized to bicarbon-
ate), and [glucose] 111Immol/l (to facili-
tate Na-glucose cotransport), for a total
osmolarity of311 mosmll. Thepatient was
given a volume of WHO-OHS equivalent
to the total stool/emesis output, collected
in graduated containers beneath a cholera
cot. The patient was also given free access
to food and water.
The total stool output in the first day
was over 12 1, but the total output over the
next two days was 4.21. The patient's diar-
rhea completely resolved 48 hours after
presentation. The patient consumed a total
of twenty-one liters ofWHO-OHS and an
additional two liters of free water. Final
laboratory analysis confirmed infection
with Vibrio cholerae, El Tor Ogawa.
THE HISTORY OF CHOLERA
Cholera has been endemic to the Indi-
an subcontinent for millennia. Spread of
cholera beyond the Indian subcontinent in
1817 marked the first worldwide pandemicKavic et al.: Cholera: medical history and science 397
(see Table 1). However, compelling
descriptions of severe diarrheal diseases
consistent with cholera dating from the
time ofHippocrates suggest the possibility
ofan even earlieremergence fromAsia [8].
In 1959, Robert Pollitzer chronicled
the first six pandemics [9]. Although reli-
able serotyping was not available prior to
the fifthpandemic, one mightpresume that
the first four pandemics were caused by
the same agent (Table 1). The first case
presented was based on cholera's first
arrival in Britain during the second pan-
demic. Vibrio cholerae 01 has two vari-
ants, the so-called classical biotype; and
the El Torbiotype, the hardier but less vir-
ulent agent ofthe seventh pandemic. Since
1992, outbreaks of cholera caused by a
new serogroup, Vibrio cholerae 0139,
have been reported in South Asia and
China, raising the prospect of an Eighth
Pandemic [10] (Table 1).
In 1854, John Snow linked a cholera
outbreak in London to a single source: a
contaminated waterpump onBroad Street.
This was the first convincing demonstra-
tion that cholera was a contagious and
water-borne disease. The removal of the
pump handle at Dr. Snow's request stands
as a landmark in the history of public
health and preventive medicine. Another
milestone in the understanding of cholera
came in 1883 when Robert Koch, discov-
erer of the etiologic agent of tuberculosis,
led an expedition to Egypt during which
he identified a microbe he called komma-
bazillen (comma bacilli) [11]. He subse-
quently detected kommabazillen in the
stools of cholera patients in Calcutta. The
name of this bacterium was later changed
to Vibrio cholerae, in belated recognition
ofFilipo Pacini, who hadbestowed the lat-
ter name on the bacillus he observed in the
excreta of cholera victims in Italy thirty
years earlier [9].
Fortunately, even before the etiologic
agent was identified, there were those com-
mitted to the notion that the spread of
cholera could be controlled ". . . not with
prayer and fasting, but through disinfection
and quarantine. [C]holera demonstrated
forcefully that a disease that could not be
cured must be prevented" [12]. From con-
victions such as these grew institutions like
New York City's Metropolitan Board of
Health, credited with containing a cholera
outbreak in 1866. The association of
cholera with unsanitary water and crowd-
ed, squalid living conditions has always
resulted in a disproportionate representa-
tion of the urban poor on its death rolls.
Perhaps it was inevitable that so dreadful a
scourge - one that generally spared the
wealthy and refined while ravaging the
Table 1.The Cholera Pandemics (based on Pollitzer, 1959 [8]).
Pandemic Time Period Serogroup Biotype Affected Areasb
First 1817to 1823 VibriocholeraeOl1 Classicala 1,2,3,5
Second 1829 to 1851 Vibrio cholerae 01 Classicala 1, 2, 3, 4, 5,6, 7
Third 1852 to 1859 Vibrio cholerae 01 Classicala 1, 2, 3, 4, 5, 6, 7, 8
Fourth 1863 to 1879 Vibrio cholerae 01 Classicala 1, 2, 3, 4, 5, 6, 7
Fifth 1881 to 1896 Vibrio cholerae 01 Classical 1, 2, 3, 4, 5, 6, 7
Sixth 1899 to 1923 Vibrio cholerae 01 Classical 1, 2, 3, 4, 5, 7
Seventh 1961 to Present Vibrio cholerae 01 El Tor 1, 2, 3, 4, 5, 8, 9
Eighth (?) 1992 to Present Vibrio cholerae 0139 Single biotype 2
a Presumed.
bAffected areas: 1, Indian Subcontinent; 2, Southeast Asia; 3, Middle East; 4, Europe; 5, East
Africa; 6, North Africa; 7, North American; 8, South America; 9, Indonesia.398 Kavic et aL: Cholera: medical history and science
impoverished and uneducated - would be
seen as divine retribution for the sinful,
profligate, and unworthy. Indeed, for prop-
er members of the upper class, Vibrio
cholerae could be both an intestinal
pathogen and a character assassin - "to
die of cholera was to die in suspicious cir-
cumstances" [13].
Over a century later, can we be sure
that a parallel situation does not exist for
patients with AIDS, who may face similar
injustices as a consequence of societal
ignorance? Long before this terrible dis-
ease challenged today's scientists explor-
ing the intricacies ofcellular signaling and
toxin-mediated disease, cholera chal-
lenged the very idea of what a "disease"
actually was, what it was not, and what
thinking citizens might do about it.
NORMAL INTESTINAL
PHYSIOLOGY
Under normal circumstances, the
human gastrointestinal tract can absorb
more than 90 percent ofthe water and ions
presented to it. To appreciate fully the
pathophysiology ofcholera, a briefreview
ofnormal water and solute handling by the
intestines is helpful.
Water: The healthy small intestine is
able to absorb about 7 - 8.5 liters of the
nine liters that enters it daily, leaving an
ileocecal flow rate of 0.5-2 Il/day. It is
important to remember that in the small
intestine, mature epithelial cells near the
tips of the villi are engaged in net absorp-
tion, while the less mature cells in
Lieberkiihn's crypts function in the net
secretion of water and electrolytes. Typi-
cally, only about 600 ml of fluid is pre-
sented to the colon per day, of which 500
ml are absorbed, leaving the 100 ml con-
tained in the average daily fecal weight of
150 g. Therefore, one functional definition
ofdiarrhea is an average daily fecal weight
exceeding 200 g. Since the colon is capa-
ble of absorbing 4 to 6 liters of water per
day, the 500 ml absorbed represents about
10 percent ofthe colon's absorptive capac-
ity.
Fluid transport in the small intestine
generally results from the passive move-
ment ofwater across epithelial membranes
driven by osmotic and hydrostatic pres-
sures. In the absence of food, ions are the
most important contributors to osmotic
pressure in the lumen. Since the cells of
the small intestine are relatively permeable
(leaky), luminal fluid generally remains
isotonic with plasma. Because most water
absorption occurs in the absence of a
transmucosal osmotic gradient, any
increase in the osmotic content of the
lumen will tend to reduce water absorption
and lead to diarrhea. Since 60 to 90 per-
cent of stool weight is water, diarrhea is
mainly due to excess fecal water.
Sodium: Sodium is actively absorbed
throughout the small intestine, the site
most affected in cholera. The favorable
electrochemical gradient (negative mem-
brane potential and low intracellular [Na])
allows sodium to enter the cell across the
apical brush border, and exit across the
basolateral membrane via the Na, K
ATPase pump. The net rate ofNa+ absorp-
tion is highest in the jejunum, where it is
enhanced by the presence of glucose,
galactose, and neutral amino acids via
Na+-sugar cotransport. Indeed, the identi-
fication of Na+-coupled cotransport sys-
tems stands as one of the most important
medical discoveries of this century, since
these processes form the basis of oral
rehydration therapy used in many parts of
the world. The net rate of Na+ absorption
is smaller in the ileum due to a lower den-
sity of cotransporter proteins.
Potassium: The movement ofpotassi-
um in the small intestine is usually in the
direction of absorption. As water is
absorbed luminal [K] rises, thereby
increasing the driving force for absorption.
It is important to note that since most K+
absorption results from its rising luminalKavic et al.: Cholera: medical history and science 399
concentration as water is absorbed, signif-
icant K+ loss may occur in diarrhea, espe-
cially in the high-flow secretory diarrhea
ofcholera.
Anions: The jejunum absorbs large
amounts of both Cl- and HCO3- anions,
and by the end of thejejunum most of the
HC03- from hepatic and pancreatic secre-
tions has been absorbed. It follows that
diseases affecting the small intestine can
result in significant HC03- losses.
PATHOPHYSIOLOGY OF CHOLERA
Cholera stimulates solute and water
secretion in the small intestine. With con-
tinuous parenteral fluid replacement, the
ileocecal flow rate may reach 15 to 20
liters per day. Such a secretory diarrheal
process can lead to severe losses of vol-
ume and electrolytes. The initial stool out-
put in cholera gravis can exceed a full liter
per hour, resulting in death in as little as
four to six hours. It has been said that
cholera is a disease that begins where
other diseases end - with death.
It is important to emphasize that since
the fluid loss in cholera is essentially iso-
tonic, "dehydration" is not the problem;
rather the patient becomes severely vol-
ume-depleted. Conceptually, it is absolute-
ly critical to distinguish hypovolemia (loss
of salt in isotonic proportions) and dehy-
dration (loss of solute-free water) [14].
Hypovolemia is assessed clinically by
physical exam and does not require any
laboratory tests, and the diagnosis of salt
(volume) depletion implies the life-saving
therapy ofisotonic salt (volume) repletion.
In contrast, "dehydration" implies solute-
free water loss, or hypertonicity, which is
a laboratory diagnosis.
Chloride secretion
The transport function of epithelia is
inextricably linked to the polarized distrib-
ution of transport elements in the apical
and basolateral membranes of epithelial
cells (Figure 2) [15]. Secretion of fluid
across the intestinal epithelium is primari-
ly driven by the net transport ofsolute into
the lumen and the secondary movement of
water down the resultant osmotic gradient.
Net transport in a preferred direction
requires an asymmetric arrangement of
transport elements; that is, cell polarity.
The transepithelial secretion of chlo-
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Figure 2. Secretory epithelial cell model. The Na, K-ATPase pump and triple ion trans-
porter are shown on the basolateral side of the cell, with the CFTR chloride channel illus-
trated on the apical membrane. This arrangement allow for secretion of chloride across the
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many secretory epithelia including the
small intestine. In secretory epithelial cells
such as those in the crypts of Lieberkuhn,
the asymmetry of Cl- transport elements
underlies Cl- secretion. The basolateral
Na,K-ATPase pump drives active Cl-
transport, and inhibitors of the pump such
as ouabain abolish Cl- secretion. The low
intracellular [Na] maintained by the pump
and the low intracellular [Cl-] favor the
entry of Cl- across the basolateral mem-
brane via a furosemide- and bumetanide-
sensitive Na:K:2Cl triple ion cotrans-
porter. The pump also maintains a high
intracellular [K], and together with the
large basolateral K+ conductance, causes
the apical and basolateral membrane
potentials to be cell-negative. This nega-
tive membrane potential provides a key
driving force for conductive Cl- exit when
chloride channels localized in the apical
membrane open.
Thus, the active secretion of Cl- by
polarized epithelia is mediated by an
asymmetric arrangement of a basolateral
Cl- entry element (the electroneutral triple
cotransporter) and an apical Cl- exit ele-
ment (a transmembrane channel). Simply
put, transcellular transport requires a way
in and a way out. Of great significance is
that the major Cl- conductance in the api-
cal membrane of secretory epithelia
(including the crypt cells) is the now
famous Cystic Fibrosis Transmembrane
conductance Regulator (CFTR)d, the pro-
tein that is defective in patients with cystic
fibrosis (CF). CFTR is a multi-functional
protein, but its characterization as a
cAMP-activated Cl- channel is well docu-
mented [16, 17]. In secretory epithelia,
continued Cl- secretion hinges on the
basolateral membrane being selectively
conductive to K+, while CFTR in the api-
cal membrane is selectively conductive to
C1-. Basolateral K+ efflux hyperpolarizes
the cell membrane potential, which
increases the driving force for Cl- secre-
tion.
From such considerations, it follows
that transcellular C1- transport is influ-
enced by the electrochemical (Nernst)
potential for K+. Assuming typical values
for intracellular and extracellular [K] of
120 mM and 4.4 mM, respectively, the
Nernst potential for potassium (EK) would
be -84 mV. However, for the hypokalemia
existing in a patient ([K] = 3.2 mM) EK
increases to -92 mV, an 8 mV hyperpolar-
ization. Under these conditions, as baso-
lateral K+ channels open to allow K+ to
recycle, the membrane potential hyperpo-
larizes'even more than with normal potas-
sium levels, which heightens the increase
in the driving force for chloride secretion
when apical CFTR Cl- channels open.
Even if EK were to remain constant,
an increase in the basolateral conductance
for K+ wouldresultinhyperpolarization of
the cell membrane potential. The presence
ofATP-sensitive K (KArp) channels in the
basolateral membrane could provide such
a mechanism [18], since an increase in
transport activity requires an increased
turnoveroftheNa,K-ATPase pump, which
tends to lower intracellular ATP levels.
Therefore, the development of
hypokalemia enhances the secretion ofC1-
into the lumen. This addition of Cl- to the
lumen then provides both an electrical dri-
ving force for the paracellular movement
of Na+ and an osmotic driving force for
water to go into the lumen. The driving
force for water flow into the lumen sub-
sists when the luminal fluid becomes iso-
osmotic, which explains why the secretory
diarrhea of cholera is essentially isotonic.
To make matters worse, the increasing
water content of the lumen "dilutes" the
luminal [K], reducing the major driving
force for K+ reabsorption, promoting fur-
ther K+ loss. The process then becomes a
vicious cycle ofisotonic Na+ (with Cl- and
HCOj) and K+ loss, resulting in progres-
sive hypovolemia, hypokalemia, and meta-
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patient dies ofhypoperfusion acidosis and
hypovolemic shock.
Cholera toxins
It is not an overstatement to say that
the entire clinical syndrome of cholera is
due to the action of the cholera toxin on
intestinal epithelial cells. Vibrio cholerae
is a non-invasive, aerobic, gram-negative
bacillus that produces the choleragen, the
cholera toxin (CTX). The organism attach-
es to the intestinal mucosa via various sur-
face adhesion components, such as toxin
coregulated pili (tcpA) [19]. The most sen-
sitive regions are in the duodenum and
upper jejunum; the ileum is less affected.
The organism does not invade the mucosal
surface, and bacteremia is virtually never
seen. CTX is cytotonic rather than cyto-
toxic, as it disrupts intracellular processes
but does not directly cause cell death.
Although Koch identified Vibrio
cholerae as the etiologic agent of cholera,
and first proposed that the disease was
toxin-mediated in 1884 [10], CTX has
only been characterized in the latterhalfof
this century. In 1959, De showed thatinoc-
ulation ofligated segments ofrabbit small
intestine with the sterile and bacteria-free
filtrate from cultures of Vibrio cholerae
caused marked distension due to the secre-
tion of isotonic fluid [20]. No distension
developed in the ligated segments from the
same rabbits injected with control medi-
um. This was the first convincing demon-
stration that Vibrio cholerae must be elab-
orating a soluble factor that itself is capa-
ble ofmediating the disease.
The toxin satisfies all of "Koch's pos-
tulates," since the toxin: (1) is present in
those affected and absent in healthy indi-
viduals, (2) can be isolated from infected
patients (in this case, from their stool) and
produced in culture, (3) is able to cause
disease when reinoculated into susceptible
hosts from pure culture, and (4) can be re-
isolated from the experimentally infected
host [21].
The precise mechanism of action is
still under investigation, but several stud-
ies have yielded information on both its
structure [22, 23] and action [24, 25, 26].
There seems to be a differential effect of
the toxin on the enterocytes: it exerts a
direct stimulatory effect on the secretory
crypt cells, and an anti-absorptive effect
on the villous cells, which both favor net
secretion. Fortunately, the decrease in
absorption is much less than the increase
in secretion, making oral rehydration ther-
apy (ORT) possible (vida infra). The colon
is usually in a state ofabsorption since it is
relatively insensitive to the toxin, but its
absorptive capacity is quickly overcome in
this "overflow" diarrhea.
The crystal structure of CTX was
recently solved [22], and it closely resem-
bles the heat-labile enterotoxin from
Escherichia coli, LT [27]. Both are het-
erotrimeric complexes, comprised of a
pentameric arrangement offive B subunits
within which the wedge-shaped A subunit
is loosely held [28]. Choleragenoid, the B
subunit pentamer of cholera toxin, directs
the enzymatic A subunit to its target by
binding to the GM1 gangliosides exposed
on the luminal surface ofintestinal epithe-
lial cells [29, 30, 31]. Interestingly, the two
enterotoxins share approximately 80 per-
cent sequence homology, but the other 20
percent may be the difference between a
self-limited disease and death. The most
significant difference between the two tox-
ins is the carboxyl terminus of the A2
chain, which helps to tether the A subunit
above the plane defined by the five B sub-
units. Apparently, it is differences such as
these that lead to the production of much
higher levels of cAMP with CTX than
with LT.
TheA subunit is the active component
of the toxin [26]. It is thought that the
entire A subunit (or a portion of it) gains
entry to the cell through the ring of the B
subunits on the apical membrane [32]. The
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subunit cleaved by proteolysis, binds to
NAD inside the cell [33, 34]. The toxin
subunit then catalyzes the addition of an
ADP-ribose from NAD to the G protein
that activates adenylyl cyclase, Gs [17, 35,
36]. The cAMP produced activates the
cAMP-dependent protein kinase (PKA),
whose catalytic subunit then phosphory-
lates apical membrane chloride channels.
There is some evidence that other proteins
are also ADP-ribosylated, but the signifi-
cance of these other additions has not yet
been determined [37].
Normalphysiology ofG-proteins
The signal transduction mechanism
involves heterotrimeric guanine nucleotide
binding (G) proteins comprised of an a
subunit, and a Py complex (see reviews
[38, 39, 40]). Typically, a first messenger
(e.g., a hormone) binds to a membrane
receptor, activating a G protein within the
membrane. The a-subunit of the activated
G protein then exchanges GTP for GDP
and dissociates from the frycomplex. This
activated a-subunit directly interacts with
an effector molecule or enzyme such as
adenylyl cyclase.
One of the remarkable features of the
a-subunit is its intrinsic GTPase enzymat-
ic activity, providing an auto-negative
feedback mechanism for regulated deacti-
vation [41]. Once the GTP is hydrolyzed
to GDP, the a-subunit may re-associate
with the fy complex, thereby turning off
the functional activity of the effector mol-
ecule.
Cholera toxin and G Proteins
Cholera toxin activates adenylyl
cyclase in at least three ways through the
ADP-ribosylation of the a-subunit [23,
42]. First, ADP-ribosylation reduces the
inherent GTPase activity of the a-subunit
by a factor of one hundred, resulting in a
tremendous increase in the production of
cAMP [43, 44]. Second, the addition of
ADP-ribose facilitates the physical disso-
ciation of the Pycomplex from the a-sub-
unit [45]. Finally, theADP-ribosylation by
cholera toxin prevents the dissociation of
the a-subunit from the activated cyclase,
keeping the enzyme locked in its active
state [42, 46].
The ADP-ribosylation by cholera
toxin requires the presence of separate
ADP-ribosylation factors, or ARFs [47,
48]. ARFs are GTP-binding proteins, nor-
mally present in cells, that function in con-
junction with the cholera toxin to increase
the level of adenylyl cyclase activity [49].
ARFs appear to be allosteric activators of
the Al peptide, interacting directly with
the toxin to stimulate its activity in vivo
[50, 51, 52]. Currently three highly con-
served classes of these factors have been
identified, anddifferentARFs maybe have
optimal activity under different environ-
mental conditions [53, 54].
Thus, the result of the action of
cholera toxin is an elevation of cAMP to
pathologically high intracellular levels
through a G protein mediator. CTX-
induced elevations in cAMP lead to an
abnormally high apical membrane chlo-
ride conductance, due to opening of the
CFTR chloride channels. Chloride can
then move down its concentration gradi-
ent, spilling from the cell in abnormally
high quantities. Due to the resultant elec-
tronegative lumen, sodium is secreted via
a paracellular pathway. This osmotic gra-
dient drives water flow into the lumen,
with the net effect being the secretion of
massive amounts ofisotonic fluid.
Cholera toxin exerts additional effects,
separate from the adenylyl cyclase system.
For instance, CTX also triggers intestinal
enterochromaffin cells to release serotonin
[55]. Serotonin may contribute to height-
ened gastrointestinal secretion by serving
as a excitatory neurotransmitter of intra-
mural neurons within the enteric nervous
system [56, 57]. VIP-containing neurons
may serve as the effectors of vasodilata-Kavic et al.: Cholera: medical history and science 403
tion, increasing mucosal perfusion and, as
a result, intestinal secretion [58, 59].
Furthermore, Vibrio cholerae pro-
duces other toxins in addition to CTX
[60]. Zonula occludens toxin (Zot)
increases intestinal permeability by weak-
ening the tight junctions that maintain the
integrity of the epithelial sheet [61]. Zot
interacts with specific cell receptors,
reversibly affecting the actin elements of
the cytoskeleton, allowing increased loss
of ions into the intestinal lumen [62].
Accessory cholera enterotoxin (Ace) also
contributes to secretory diarrhea, possibly
by opening channels and increasing the
potential difference across the apical
membrane [63]. Pathogenic strains ofVib-
rio cholerae may also produce a sodium
channel inhibitor [64]. These additional
toxins have a supplementary role to CTX





The impact of cholera goes well
beyond the clinical syndrome of cholera
gravis. To the present day, cholera contin-
ues to challenge definitions ofdisease and
the underlying mechanisms that maintain
diseases within the human population. On
a fundamental level, the most important
question is why certain diseases (like cys-
tic fibrosis) exist at all, and to answer it,
we are again confronted with the problem
of cholera.
In select circumstances, there can be a
theoretical advantage to heterozygosity for
adamaging trait, when this combination of
alleles protects the carrier from another
severe disorder. In perhaps the best known
example, heterozygotes for the abnormal
protein Hemoglobin S do not have sickle
cell anemia, but are protected to a certain
degree against malaria [65]. Thus, there
exists a "heterozygote advantage" that
maintains the frequency of this otherwise
deleterious recessive gene in the general
population.
A similar advantage has been hypoth-
esized for the diseases of cholera and cys-
tic fibrosis (CF) [66, 67, 68]. In CF, the
apical chloride channel (CFTR) is hyper-
active or inactive, preventing the direct
transport of chloride across cellular mem-
branes [69, 70]. This homozygous reces-
sive disorder occurs at a frequency of one
in 2500 Caucasian live births, an alarm-
ingly high rate given the severity of the
disease [71]. This high rate is inadequate-
ly explained by the effects of genetic
mutation or by a fertility difference of the
carriers [72, 73].
Heterozygotes for CF have some
abnormal channels due to the mutant gene,
as well as normal channels due to the wild-
type gene. In the absence of infection or
severe stressors, the heterozygote would
sufferfew clinically evident abnormalities,
due to the presence of the subset of nor-
mally functioning channels [74]. However,
it is possible that when heterozygotes for
CF become infected with Vibrio cholerae,
the increase in apical chloride conductance
is blunted, thereby attenuating the massive
loss of salt associated with those cholera
victims having a full complement of nor-
mal CFTR channels [75, 76]. A recent
experiment confirmed this hypothesis
using transgenic mice, showing that chlo-
ride secretion was directly correlated to
the number ofCFTR alleles [77]. Howev-
er, other experiments have not provided as
conclusive data [78].
Cholera has remained a scourge
throughout the latter halfofthe last centu-
ry. Considering the time scale necessary
for adaptation, not enough time has passed
to remove the allele from the gene pool
[2]. Thus, it is possible that CF continues
to exist in the human population because
heterozygosity for this disorder is to some
extent protective against cholera.404 Kavic et al.: Cholera: medical history and science
TREATMENT
Death from cholera gravis results
from untreated hypovolemic shock with
metabolic acidosis. The cornerstones of
therapy are 1) to give thepatientbackwhat
is lost - a lot of isotonic fluid - as the
villagers believed; and 2) to stop the loss-
es. To replete the lost substances in 1831,
physicians attempted intravenous volume
resuscitation. However, ifthey would have
known about Na-coupled glucose trans-
port, they could have made an oral rehy-
drating solution containing NaCl, KCl,
and bicarbonate of soda of the same com-
position as what the patient was losing,
along with glucose.
For this reason alone, the identifica-
tion of sodium-coupled epithelial cotrans-
port processes was a major medical break-
through. Although Reid had provided
experimental evidence supporting the
transport of sugars against a concentration
difference at the turn of the century [79],
the dependence on luminal sodium was
first observed by Riklis and Quastel in the
late 1950s [80]. In the early 1960s, Crane
and colleagues advanced these ideas and
showed that sodium-dependent sugar
cotransport occurred in the luminal brush
border of small intestinal epithelial cells
[81, 82]. The first ofthe family ofsodium-
glucose transporters was subsequently
cloned from rabbit small intestine by
Wright and coworkers in 1987 [83].
Normally the sodium-coupled trans-
porters utilize the large electrochemical
gradient of sodium to drive absorption of
sugars and other nutrients (e.g., amino
acids). Although cholera toxin biases the
system strongly in the direction of secre-
tion, reabsorptive processes are largely left
intact. In fact, one study involving total
intestinal perfusion with cholera toxin in
human volunteers demonstrated a dou-
bling ofnet sodium cotransport afterexpo-
sure to CT [84]. Therapy with ORS takes
advantage ofcotransport, byusing sugar to
drive the reabsorption ofsalt. This attempt
at restoring balance to a hyperactive secre-
tory system can be lifesaving.
To stop the losses in cholera, the
source ofthe infection must be eliminated.
Fortunately, the Vibrio infection itself is
self-limited; that is, bacteria do not remain
active in the intestinal tract for extended
periods of time. Although antibiotics may
decrease the severity of the clinical symp-
toms or otherwise diminish the course of
the illness, in most cases they are not
essential to the treatment of the disorder.
Therefore, in developing countries or in
those in which medicine is in short supply,
a regimen of ORS will permit the survival
ofthe vast majority ofthose infected [85],
as in case scenario [3].
In the present day, most physicians
would begin treatment with intravenous
isotonic saline, bicarbonate replacement,
and antibiotics (tetracycline, doxycycline,
or ciprofloxacin [86]). It should be
stressed, however, that ORS would and
does work. ORS is particularly valuable in
countries where cholera is endemic and
can be pandemic, as recently seen in Peru
in 1991.
SUMMARY
Cholera has been a scourge of
humankind, claiming millions of lives
from antiquity to the present day. The his-
tory of cholera is also associated with the
development of several medical break-
throughs (e.g., intravenous solution thera-
py, basic sanitation, oral rehydration ther-
apy) that have saved millions of lives.
Study of the cholera toxin continues to
provide great insights into the cellular
basis of diseases, the molecular mecha-
nisms of signal transduction systems
involving G-proteins, and our understand-
ing of epithelial transport. Such progress
has rendered cholera a curable disease.
Despite this level of advancement, it is
paradoxical that the fate of people with
cholera in underdeveloped parts of theKavic et al.: Cholera: medical history and science 405
world is no different from that of the
unfortunate patient in 1831.
EPILOGUE
In 1831, intravenous therapy was not
available. Indeed, it was during the cholera
epidemic in Sunderland in 1831 that the
idea of intravenous therapy was proposed
by Dr. William Brooke O'Shaughnessy, a
22-year-old graduate of Edinburgh, in a
paper on cholera to the Westminster Med-
ical Society. This wasn't attempted until
1832 when Dr. Thomas Latta "dissolved
from two to three drachms of muriate of
soda and two scruples ofthe subcarbonate
of soda in six pints of water, and injected
it at temperature 1120 Fah." (The Lancet of
June 2, 1832). In modem units, this is
about [Na] 58 meq/l, [Cl] 49 meq/l, and
[HCO3-i 9 meq/l [87]. Although they
didn't have antibiotics, they did have salts
and sugars, and thus an oral rehydration
solution would have worked.
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